Aberrant gene expression can lead to human disease. Our research group aims to understand how disease-relevant genes are post-transcriptionally regulated and to develop novel therapies to drug the undruggable at RNA biology level. For instance, we are interested in influencing splicing choices, mRNA translation efficiency or changing the affinity of RNA-protein interactions that drive certain post-transcriptional regulation steps. Our approach is highly integrated and iterative, spanning a variety of chemical biology technologies such as high throughput screening, biochemical and cell-based functional assays, high throughput transcriptomics and next generation sequencing, structural and biophysical approaches, chemistry and computational biology. We collaborate extensively with other groups at Novartis and academic institutions, and together we build relevant tools and knowledge to treat human disease.